Clinical Trial Update: A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for Inlexisertib (DCC-3116) in combination with anticancer therapies in participants with advanced malignancies, including gas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Inlexisertib (DCC-3116) (Inlexisertib)

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: GIST | Phase 1, Phase 2 | Status: RECRUITING